PharmaVOICE - 
April 2008
Purchase Issue

In Every Issue
Last Word
James King,M.D.,FAAFP,was named Presidentelect of the American Academy of Family [...]
By
Talent Pool
previously served as VP, pharmaceutical sci ences quality. She earned [...]
By
On the Calendar
Managing MultiJurisdictional Legal and Regulatory Risks in Clinical Trials Renaissance [...]
By
E-Media
NEW ELECTRONIC AND WEBBASED APPLICATIONS, SITES, AND TECHNOLOGIES Clinical Ink [...]
By
What’s New
NEW HEALTHCARERELATED PRODUCTS, SERVICES, AND COMPANIES Publicis Selling Solutions Group [...]
By
PharmaTrax
GOLD STANDARD IN ASTHMA TREATMENT is Expected to Emerge A [...]
By
PharmaOutlet
It’s time to take a fresh look at a big [...]
By

Shelley Spencer

UpFront
Milestones 20 YEARS OF DISCOVERY Pharmaceutical Research and Manufacturers of [...]
By
Raise Your Voice — Letters
A Missing Link I just finished reading the March article, [...]
By
Letter from the Editor
Bogey and Bacall, Rogers and Hammerstein,Ben & Jerry,or closer to [...]
By

On The Cover

Global Clinical Connections
Building Relationship Bridges Forming a winning CRO/sponsor partnership requires trust, communication, and understand ing the expectations and needs of the other party. Using advanced technology for communi cations, taking ownership, and getting to know your partner can ensure these elements are front and center of the relationship. GUTHRIE. XCELIENCE. Probably the single most important element [...]
By

Robin Robinson

Features

Competitive Counter-Strike
In December 1999, ParkeDavis (now Pfizer) launched Lipitor, a very potent LDL cholesterollowering agent. Despite being the fifth statin to enter the U.S. market, Pfizer overwhelmed the competition and soon made Lipitor the topselling cholesterol and pharmaceutical product in the world. By 2002, AstraZeneca was preparing to launch Crestor, a new statin with even greater [...]
By
Janet Greeson — A Good Samaritan
company had come about from consulting with a doctor who asked her to write about an HIV drug, SP01A, one of the candidates in Samaritan’s pipeline. “I became so interested in the drug, that eventually I found myself pretty much running Steroidogenesis,” she says. The first thing she did upon taking the helm, was to [...]
By

Kim Ribbink

25 Years of the Orphan Drug Act
Synthetic drugs accounted for 62% of total orphan drug approvals, and synthetic polypep tides and hormones together accounted for 6%. Among biologics, growth hormones and growth factors together have the largest num ber of approvals at 8% of the total. Market approvals received for plasma products BY CYNTHIA BORDA Cot, M.D., MPH, director of the [...]
By

Cynthia Borda

Licensed to Sell
A NEW LEGISLATION PROPOSES THAT SALES REPS OBTAIN LICENSES BEFORE THEY CAN MEET WITH PHYSICIANS. The law currently may cause ripples only in Washington,D.C.,but some experts believe its implications will be far reaching. BY ROBIN ROBINSON 0408 Layout PROOFS 3/25/08 11:45 AM Page 58 59 PharmaVOICE Ap r i l 2 008 SALES REP legislation [...]
By

Robin Robinson

The Softer Side of R&D
Industry experts say the technical competencies of drug development have to be combined with the softer skills of change management and leadership ability. R&D leaders will have to work in global teams to manage the output from their partners. This will require highly trained technical specialists who have strong interpersonal and communications skills. Working in [...]
By

Denise Myshko

Agency Client Services
A SHIFTING LANDSCAPE We asked our agency executives to evaluate what they believe have been the biggest shifts in client service in the past five years. We also asked them to project what they believe the client service role will encompass in the next fiveyears. HOWDOYOUMANAGECLIENTCHALLENGES? DUNN. VOX MEDICA. Time is, and always has been, [...]
By

Taren Grom, Editor

Proof of Concept
BENEFITS OF EXPLORATORY INDS In a guidance released in January 2006, the FDA laid out specific approaches for researchers George Mills, M.D., VP, medical imaging consulting, for Perceptive Informatics at Parexel International, agrees that an exploratory IND is an avenue to evaluate the preclinical assessments for investigational drugs and biologics in human subjects. These confirmatory [...]
By

Denise Myshko

FEEDBACK